AbbVie shells out $440M on two PRVs for label expansions of its blockbuster Rinvoq
The priority review voucher market can be notoriously secretive, especially when companies purchase PRVs and don’t disclose where they’re planning to use the expedited FDA reviews.
For AbbVie, that strategy has been plain and simple so far: expand blockbuster Rinvoq’s label as quickly as possible.
Back in 2015, the Chicago-based biotech spent an eye-opening $350 million on a PRV from United Therapeutics — more than any other PRV sold ever — and used it to win approval for Rinvoq as a treatment for adults with moderately to severely active rheumatoid arthritis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.